StreetInsider.com News Articles

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: RA Capital Healthcare Fund LP

Mon, 15 Jun 2026 20:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26649137.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: RA Capital Healthcare Fund LP

Mon, 15 Jun 2026 20:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26649137.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: Scheiner Zachary

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649127.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: Scheiner Zachary

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649127.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: Thunen Shelley B

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649128.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: Thunen Shelley B

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649128.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: MCCOLLUM JAMES W

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649129.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: MCCOLLUM JAMES W

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649129.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: Guerard Frederic

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649130.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: Guerard Frederic

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649130.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: Drapkin Kimberlee C

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649132.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: Drapkin Kimberlee C

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649132.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: George Jeffrey P.

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649133.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: George Jeffrey P.

Mon, 15 Jun 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260615/26649133.html

Form 8-K LENZ Therapeutics, Inc. For: Jun 12

Fri, 12 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260612/26640797.html

Form 8-K LENZ Therapeutics, Inc. For: Jun 12

Fri, 12 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260612/26640797.html

LENZ Therapeutics Inc (LENZ) PT Lowered to $38 at H.C. Wainwright

Tue, 12 May 2026 06:54:23 -0400

(Updated - May 12, 2026 6:54 AM EDT)

H.C. Wainwright analyst Matthew Caufield lowered the price target on LENZ Therapeutics Inc (NASDAQ: LENZ) to $38.00 (from $48.00) while maintaining a Buy rating.

The analyst commented: "With the broad launch of topical presbyopia eye drop VIZZ beginning in 4Q25, we underscore our expectation for the launch trajectory to play out over several quarters as prescribers and patients continue to build progressive awareness and engagement around the product, from our perspective. We note VIZZ represents the first novel pupil selective miotic aceclidine drop, offering reading glasses patients a daily drop alternative while providing all-day

LENZ Therapeutics Inc (LENZ) PT Lowered to $38 at H.C. Wainwright

Tue, 12 May 2026 06:54:23 -0400

(Updated - May 12, 2026 6:54 AM EDT)

H.C. Wainwright analyst Matthew Caufield lowered the price target on LENZ Therapeutics Inc (NASDAQ: LENZ) to $38.00 (from $48.00) while maintaining a Buy rating.

LENZ Therapeutics Inc (LENZ) PT Lowered to $20 at Citi

Tue, 12 May 2026 05:23:15 -0400

Citi analyst Yigal Nochomovitz lowered the price target on LENZ Therapeutics Inc (NASDAQ: LENZ) to $20.00 (from $26.00) while maintaining a Buy rating.

Piper Sandler Downgrades LENZ Therapeutics Inc (LENZ) to Neutral

Tue, 12 May 2026 03:10:29 -0400

Piper Sandler analyst Biren Amin downgraded LENZ Therapeutics Inc (NASDAQ: LENZ) from Overweight to Neutral with a price target of $12.00 (from $39.00).

The analyst comments: “This afternoon, LENZ reported 1Q26 earnings. Revenues were $1.9M ($1.7M VIZZ + $0.2M Lunatus payment) derived from 25K paid rxs (19%+ QoQ) written by 10K+ ECPs (60% prescribing multiple times). Positive launch signals include 2/3 of e-pharmacy volume now in 3-packs. That said, the pace of new patient starts and routine prescribing remains more gradual than expected. It seems there's an inherent market issue where prescribers are not offering the potential to their presbyope patient

Piper Sandler Downgrades LENZ Therapeutics Inc (LENZ) to Neutral

Tue, 12 May 2026 03:10:29 -0400

Piper Sandler analyst Biren Amin downgraded LENZ Therapeutics Inc (NASDAQ: LENZ) from Overweight to Neutral with a price target of $12.00 (from $39.00).

LENZ Therapeutics, Inc. (LENZ) Misses Q1 EPS by 132c

Mon, 11 May 2026 16:32:59 -0400

LENZ Therapeutics, Inc. (NASDAQ: LENZ) reported Q1 EPS of ($1.32). Revenue for the quarter came in at $1.9 million.

For earnings history and earnings-related data on LENZ Therapeutics, Inc. (LENZ) click here.

Form 10-Q LENZ Therapeutics, Inc. For: Mar 31

Mon, 11 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260511/26469146.html

Form 10-Q LENZ Therapeutics, Inc. For: Mar 31

Mon, 11 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260511/26469146.html

Form 8-K LENZ Therapeutics, Inc. For: May 11

Mon, 11 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260511/26469049.html